Chemokines in atherosclerosis: an update - PubMed (original) (raw)
Review
. 2008 Nov;28(11):1897-908.
doi: 10.1161/ATVBAHA.107.161174. Epub 2008 Jun 19.
Affiliations
- PMID: 18566299
- DOI: 10.1161/ATVBAHA.107.161174
Review
Chemokines in atherosclerosis: an update
Alma Zernecke et al. Arterioscler Thromb Vasc Biol. 2008 Nov.
Abstract
The fundamental importance of chemokines for atherogenesis, progression, and destabilization of atherosclerotic plaques is now widely appreciated, but the degree of complexity, specificity, and cooperativity harnessed by these signal molecules to govern atherogenic cell recruitment and homeostasis is still being refined. Since the role of chemokines in atherosclerotic vascular disease has been reviewed in this journal, significant progress has been accomplished in defining the regulation of chemokine expression and function in atherosclerosis. In this update, we will highlight these recent developments, in particular the identification of components regulating the transcriptional machinery of the proatherogenic chemokine CCL5, distinct roles of its receptors CCR1 and CCR5 in plaque formation and immunobalance, and differential site- and stage-specific effects of T cell-activating chemokines and their receptors, eg, CXCL10 and CXCR3. The contribution of the transmembrane chemokines CX(3)CL1 and CXCL16 with their respective receptors CX(3)CR1 and CXCR6 in the recruitment of T cell and monocyte subsets and shear-mediated plaque modulation will be discussed. Finally, the role of CXCR2 and CXCR4, their respective ligands CXCL1 and CXCL12, and the noncanonical dual agonist MIF in atheroprogression will be dissected. The considerable leap in insight over recent years leads us to anticipate further advances in comprehending the role of chemokines in atherosclerosis, allowing targeted interventions for its prevention and therapy.
Similar articles
- Lymphocyte migration into atherosclerotic plaque.
Li J, Ley K. Li J, et al. Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):40-9. doi: 10.1161/ATVBAHA.114.303227. Epub 2014 Oct 9. Arterioscler Thromb Vasc Biol. 2015. PMID: 25301842 Free PMC article. Review. - Inflammatory mediators in atherosclerotic vascular disease.
Zernecke A, Weber C. Zernecke A, et al. Basic Res Cardiol. 2005 Mar;100(2):93-101. doi: 10.1007/s00395-005-0511-6. Epub 2005 Jan 10. Basic Res Cardiol. 2005. PMID: 15645164 Review. - Chemokines in the vascular inflammatory response of atherosclerosis.
Zernecke A, Weber C. Zernecke A, et al. Cardiovasc Res. 2010 May 1;86(2):192-201. doi: 10.1093/cvr/cvp391. Epub 2009 Dec 9. Cardiovasc Res. 2010. PMID: 20007309 Review. - MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.
Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C. Bernhagen J, et al. Nat Med. 2007 May;13(5):587-96. doi: 10.1038/nm1567. Epub 2007 Apr 15. Nat Med. 2007. PMID: 17435771 - Chemokines in vascular dysfunction and remodeling.
Schober A. Schober A. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1950-9. doi: 10.1161/ATVBAHA.107.161224. Epub 2008 Sep 25. Arterioscler Thromb Vasc Biol. 2008. PMID: 18818421 Review.
Cited by
- Circulating CXCL9, monocyte percentage, albumin, and C-reactive protein as a potential, non-invasive, molecular signature of carotid artery disease in 65+ patients with multimorbidity: a pilot study in Age.It.
Capri M, Fronterrè S, Collura S, Giampieri E, Carrino S, Feroldi FM, Ciurca E, Conte M, Olivieri F, Ullo I, Pini R, Vacirca A, Astolfi A, Vasuri F, La Manna G, Pasquinelli G, Gargiulo M. Capri M, et al. Front Endocrinol (Lausanne). 2024 Jul 23;15:1407396. doi: 10.3389/fendo.2024.1407396. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39109084 Free PMC article. - Investigating the therapeutic effects and mechanisms of Carthamus tinctorius L.-derived nanovesicles in atherosclerosis treatment.
Yang R, Lin F, Wang W, Dai G, Ke X, Wu G. Yang R, et al. Cell Commun Signal. 2024 Mar 12;22(1):178. doi: 10.1186/s12964-024-01561-6. Cell Commun Signal. 2024. PMID: 38475787 Free PMC article. - In silico based analysis to explore genetic linkage between atherosclerosis and its potential risk factors.
Hridoy HM, Haidar MN, Khatun C, Sarker A, Hossain MP, Aziz MA, Hossain MT. Hridoy HM, et al. Biochem Biophys Rep. 2023 Nov 7;36:101574. doi: 10.1016/j.bbrep.2023.101574. eCollection 2023 Dec. Biochem Biophys Rep. 2023. PMID: 38024867 Free PMC article. - Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases.
Xu P, Cai X, Guan X, Xie W. Xu P, et al. Pharmacol Ther. 2023 Nov;251:108540. doi: 10.1016/j.pharmthera.2023.108540. Epub 2023 Sep 28. Pharmacol Ther. 2023. PMID: 37777160 Review. - Therapeutic inhibition of CXCR1/2: where do we stand?
Sitaru S, Budke A, Bertini R, Sperandio M. Sitaru S, et al. Intern Emerg Med. 2023 Sep;18(6):1647-1664. doi: 10.1007/s11739-023-03309-5. Epub 2023 May 30. Intern Emerg Med. 2023. PMID: 37249756 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous